Comparison of demographics, treatment patterns, health care utilization, and costs among elderly patients with extensive-stage small cell and metastatic non-small cell lung cancers

BMC Health Services Research

Volumn 14, Issue 1, 2014, Pages

  Karve, Sudeep J ^a   Price, Gregory L ^b   Davis, Keith L ^a   Pohl, Gerhardt M ^b   Smyth, Emily Nash ^b   Bowman, Lee ^b  

^a RTI HEALTH SOLUTIONS   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Health care costs; Health care utilization; Metastatic lung cancer; SEER medicare

Indexed keywords

AGED; CARCINOMA, NON-SMALL-CELL LUNG; COHORT ANALYSIS; COMPARATIVE STUDY; ECONOMICS; FEMALE; HEALTH CARE COST; HOSPICE CARE; HUMAN; MALE; PATIENT ATTITUDE; RETROSPECTIVE STUDY; SMALL CELL LUNG CARCINOMA; STATISTICS AND NUMERICAL DATA; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; FEMALE; HEALTH CARE COSTS; HOSPICE CARE; HUMANS; MALE; PATIENT ACCEPTANCE OF HEALTH CARE; RETROSPECTIVE STUDIES; SMALL CELL LUNG CARCINOMA; UNITED STATES;

EID: 84988640914     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/s12913-014-0555-8     Document Type: Article

References (48)

1. Siegel R, MA J, Zou Z, Jemal A: Cancer statistics. CA Cancer J Clin 2014, 64:9-29.
2. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK: SEER Cancer Statistics Review: 1975-2008. [http://seer.cancer.gov/csr/1975-2008/]
3. National Comprehensive Cancer Network: NCCN Guidelines for Patients: Non-small Cell Lung Cancer. Version 1. 2014. [http://www.nccn.org/ patients/guidelines/nscl/#1]
4. Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow L, Downey RJ, Gandhi L, Ganti AK, Govindan R, Grecula JC, Hayman J, Heist RS, Horn L, Jahan TM, Koczywas M, Moran CA, Niell HB, O'Malley J, Patel JD, Ready N, Rudin CM, Williams CC Jr, National Comprehensive Cancer Network: Small cell lung cancer. J Natl Compr Canc Netw 2011, 9:1086-1113.
5. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML: Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011, 103:117-128.
6. Graham P, Boyages J: Economic and quality-of-life aspects of treating small cell lung cancer. Pharmacoeconomics 1993, 3:446-453.
7. Rosenthal MA, Webster PJ, Gebeski VJ, Stuart-Harris RC, Langlands AO, Boyages J: The cost of treating small cell lung cancer. Med J Aust 1992, 156:605-610.
8. Carlson JJ, Reyes C, Oestreicher N, Lubeck D, Ramsey SD, Veenstra DL: Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (mNSCLC). Lung Cancer 2008, 61:405-415.
9. Hoverman JR, Robertson SM: Lung cancer: a cost and outcome study based on physician practice patterns. Dis Manag 2004, 7:112-123.
10. Lang K, Marciniak MD, Faries D, Stokes M, Buesching D, Earle C, Treat J, Babineaux S, Morissette N, Thompson D: Costs of first-line doublet chemotherapy and lifetime medical care in advanced non-small-cell lung cancer in the United States. Value Health 2009, 12:481-488.
11. Chang S, Long SR, Kutikova L, Bowman L, Finley D, Crown WH, Bennett CL: Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999-2000. J Clin Oncol 2004, 22:3524-3530.
12. Kutikova L, Bowman L, Chang S, Long SR, Obasaju C, Crown WH: The economic burden of lung cancer and the associated costs of treatment failure in the United States. Lung Cancer 2005, 50:143-154.
13. Ramsey SD, Martins RG, Blough DK, Tock LS, Lubeck D, Reyes CM: Second-line and third-line chemotherapy for lung cancer: use and cost. Am J Manag Care 2008, 14:297-306.
14. Davidoff AJ, Tang M, Seal B, Edelman MJ: Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:2191-2197.
15. Duh MS, Reynolds Weiner J, Lefebvre P, Neary M, Skarin AT: Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis. Curr Med Res Opin 2008, 24:967-974.
16. Stokes ME, Muehlenbein CE, Marciniak MD, Faries DE, Motabar S, Gillespie TW, Lipscomb J, Knopf KB, Buesching DP: Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer. J Manag Care Pharm 2009, 15:669-682.
17. Ramsey SD, Howlader N, Etzioni RD, Donato B: Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare. J Clin Oncol 2004, 22:4971-4978.
18. Cipriano LE, Romanus D, Earle CC, Neville BA, Halpern EF, Gazelle GS, McMahon PM: Lung cancer treatment costs, including patient responsibility, by disease stage and treatment modality, 1992 to 2003. Value Health 2011, 14:41-52.
19. National Cancer Institute: SEER Fact Sheets and Brochures. [http://seer. cancer.gov/about/factsheets/SEER-brochure.pdf]
20. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, Spitznagel EL, Piccirillo J: Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006, 24:4539-4544.
21. Young JL Jr, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA: SEER Summary Staging Manual-2000: Codes and Coding Instructions. In Bethesda, MD, National Cancer Institute, NIH publication No. 01-4969, 2001, NIH publication No. 01-4969. Bethesda, MD: National Cancer Institute; 2001.
22. Hershman D, Hall MJ, Wang X, Jacobson JS, McBride R, Grann VR, Neugut AI: Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer. Cancer 2006, 107:2581-2588.
23. Sundararajan V, Hershman D, Grann VR, Jacobson JS, Neugut AI: Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study. J Clin Oncol 2002, 20:173-178.
24. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA: Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005, 43:1130-1139.
25. Weycker D, Malin J, Kim J, Barron R, Edelsberg J, Kartashov A, Oster G: Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study. Clin Ther 2009, 31:1069-1081.
26. Heaney ML, Toy EL, Vekeman F, Laliberté F, Dority BL, Perlman D, Barghout V, Duh MS: Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia. Cancer 2009, 115:4839-4848.
27. Heigener DF, Manegold C, Jäger E, Saal JG, Zuna I, Gatzemeier U: Multicenter randomized open-label phase III study comparing efficacy, safety, and tolerability of conventional carboplatin plus etoposide versus dose-intensified carboplatin plus etoposide plus lenograstim in small-cell lung cancer in "extensive disease" stage. Am J Clin Oncol 2009, 32:61-64.
28. Jiang J, Liang X, Zhou X, Huang L, Huang R, Chu Z, Zhan Q: A metaanalysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer. J Thorac Oncol 2010, 5:867-873.
29. Mascaux C, Paesmans M, Berghmans T, Branle F, Lafitte JJ, Lemaitre F, Meert AP, Vermylen P, Sculier JP: European Lung Cancer Working Party (ELCWP); European Lung Cancer Working Party (ELCWP): A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 2000, 30:23-36.
30. Okamoto H, Watanabe K, Kunikane H, Yokoyama A, Kudoh S, Asakawa T, Shibata T, Kunitoh H, Tamura T, Saijo N: Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer 2007, 97:162-169.
31. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N, Japan Clinical Oncology Group; Japan Clinical Oncology Group: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002, 346:85-91.
32. Hanna N, Bunn PA Jr, Langer C, Einhorn L, Guthrie T Jr, Beck T, Ansari R, Ellis P, Byrne M, Morrison M, Hariharan S, Wang B, Sandler A: Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006, 24:2038-2043.
33. Lara PN Jr, Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, Jett J, Langer CJ, Kuebler JP, Dakhil SR, Chansky K, Gandara DR: Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensivestage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009, 27:2530-2535.
34. von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, Stewart DJ, Clark PI, Palmer MC, Depierre A, Carmichael J, Krebs JB, Ross G, Lane SR, Gralla R: Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999, 17:658-667.
35. O'Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cuceviá B, Juhasz G, Thatcher N, Ross GA, Dane GC, Crofts T: Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006, 24:5441-5447.
36. Adams JR, Lyman GH, Djubegovic B, Feinglass J, Bennett CL: G-CSF as prophylaxis of febrile neutropenia in SCLC. Expert Opin Pharmacother 2002, 3:1273-1281.
37. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology (NCCN guidelines): Myeloid Growth Factors, Version I. 2012.
38. Lyman GH, Kleiner JM: Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemothearpy. JCCN 2007, 5:217-228.
39. Rodgers GM: A perspective on the evolution of management of cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw 2012, 10:434-437.
40. Shapira I, Raftopoulos H, Gralla RJ, Pelc K, Gleason K: The impact of randomized trial results and altered regulatory policies on ESA use, transfusions, and thrombosis: A longitudinal analysis over a 3-year period of resource utilization data from a large comprehensive oncology program. ASCO Annu Meet Proc 2009, 27(15S):6611.
41. Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H: Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 2007, 15:497-503.
42. Glaus A, Knipping C, Morant R, Böhme C, Lebert B, Beldermann F, Glawogger B, Ortega PF, Hüsler A, Deuson R: Chemotherapy-induced nausea and vomiting in routine practice: a European perspective. Support Care Cancer 2004, 12:708-715.
43. Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N: A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer. Health Technol Assess 2001, 5:1-195.
44. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology (NCCN guidelines): Non-Small Cell Lung Cancer. 2012.
45. Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D, Giaccone G, American Society of Clinical Oncology: American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009, 27:6251-6266.
46. Chu Q, Vincent M, Logan D, Mackay JA, Evans WK, Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care; Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidencebased Care: Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline. Lung Cancer 2005, 50:355-3574.
47. Le Chevalier T, Scagliotti G, Natale R, Danson S, Rosell R, Stahel R, Thomas P, Rudd RM, Vansteenkiste J, Thatcher N, Manegold C, Pujol JL, van Zandwijk N, Gridelli C, van Meerbeeck JP, Crino L, Brown A, Fitzgerald P, Aristides M, Schiller JH: Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 2005, 47:69-80.
48. Pujol JL, Barlesi F, Daurès JP: Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A metaanalysis of phase III randomized trials. Lung Cancer 2006, 51:335-345.